東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

The role of matriptase and its inhib...

Oberst, Michael D.

FindBook

Google Book

Amazon

博客來

The role of matriptase and its inhibitor HAI-1 in breast cancer growth, invasion, and metastasis.

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	The role of matriptase and its inhibitor HAI-1 in breast cancer growth, invasion, and metastasis./
作者:	Oberst, Michael D.
面頁冊數:	361 p.
附註:	Mentor: Michael D. Johnson.
Contained By:	Dissertation Abstracts International64-01B.
標題:	Biology, Cell. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3077286
ISBN:	0493976647

The role of matriptase and its inhibitor HAI-1 in breast cancer growth, invasion, and metastasis.
Oberst, Michael D.

The role of matriptase and its inhibitor HAI-1 in breast cancer growth, invasion, and metastasis. - 361 p.

Mentor: Michael D. Johnson.

Thesis (Ph.D.)--Georgetown University Medical Center, 2002.

Matriptase is a type II transmembrane serine protease that might play a role in the progression of numerous types of cancer, including breast cancer. As an inhibitor of matriptase, hepatocyte growth factor activator inhibitor-1 (HAI-1) could prevent tumor progression. To determine whether matriptase expression, matriptase activity, or the matriptase-to-HAI-1 ratio correlates with tumor progression, the expression of matriptase and HAI-1 were examined both in normal human tissues and in primary human tumors and cultured cell lines. Matriptase protein levels in primary human tumors were similar to those found in normal human tissues. However, an increase in the level of the activated form of the enzyme was found in the absence of compensatory changes in HAI-1 in some breast tumor cells compared to surrounding normal breast epithelia, indicating that matriptase activity may be higher in tumor cells. In addition, a study of ovarian tumors of varying clinical stages indicated that the matriptase-to-HAI-1 protein level was more frequently elevated in later stage ovarian cancer.

ISBN: 0493976647Subjects--Topical Terms:

1017686
Biology, Cell.

The role of matriptase and its inhibitor HAI-1 in breast cancer growth, invasion, and metastasis.
LDR:03393nam 2200289 a 45 001 935700
005 20110510
008 110510s2002 eng d
020 $a 0493976647
035 $a (UnM)AAI3077286
035 $a AAI3077286
040 $a UnM $c UnM
100 1 $a Oberst, Michael D. $3 1259406
245 1 0 $a The role of matriptase and its inhibitor HAI-1 in breast cancer growth, invasion, and metastasis.
300 $a 361 p.
500 $a Mentor: Michael D. Johnson.
500 $a Source: Dissertation Abstracts International, Volume: 64-01, Section: B, page: 0032.
502 $a Thesis (Ph.D.)--Georgetown University Medical Center, 2002.
520 $a Matriptase is a type II transmembrane serine protease that might play a role in the progression of numerous types of cancer, including breast cancer. As an inhibitor of matriptase, hepatocyte growth factor activator inhibitor-1 (HAI-1) could prevent tumor progression. To determine whether matriptase expression, matriptase activity, or the matriptase-to-HAI-1 ratio correlates with tumor progression, the expression of matriptase and HAI-1 were examined both in normal human tissues and in primary human tumors and cultured cell lines. Matriptase protein levels in primary human tumors were similar to those found in normal human tissues. However, an increase in the level of the activated form of the enzyme was found in the absence of compensatory changes in HAI-1 in some breast tumor cells compared to surrounding normal breast epithelia, indicating that matriptase activity may be higher in tumor cells. In addition, a study of ovarian tumors of varying clinical stages indicated that the matriptase-to-HAI-1 protein level was more frequently elevated in later stage ovarian cancer.
520 $a To test the hypothesis that the matriptase-to-HAI-1 protein level in cultured breast cancer cells is directly involved in measures of tumor progression, inducible and stable over-expression systems were created for both matriptase and HAI-1 in MCF-7 and MDA MB-435 breast cancer cell lines, respectively. Both the MCF-7 and MDA MB-435 cell systems failed to show any effect of matriptase over-expression on measures of tumor progression such as <italic>in vitro </italic> cell growth, morphology, motility, and matrix degradation, or <italic> in vivo</italic> tumor growth, invasion, and metastasis. The over-expression of HAI-1 in tet-off MCF-7 cells suggests that HAI-1 moderately slows the proliferation of these cells, but did not affect other measures such as <italic>in vitro </italic> cellular motility and <italic>in vivo</italic> tumor growth, invasion and metastasis. Expression of HAI-1 in MDA MB-435 cells, however, profoundly inhibited both <italic>in vitro</italic> cell proliferation and <italic>in vivo</italic> tumor growth. Expression of the inhibitor did not appear to affect <italic>in vitro</italic> cell motility or <italic>in vivo</italic> tumor metastasis, although metastatic disease tended to lack HAI-1 expression, in contrast to primary tumor xenografts, suggesting that HAI-1 expression may have been turned off during the metastatic process.
590 $a School code: 0544.
650 4 $a Biology, Cell. $3 1017686
650 4 $a Health Sciences, Oncology. $3 1018566
690 $a 0379
690 $a 0992
710 2 0 $a Georgetown University Medical Center. $3 1021821
773 0 $t Dissertation Abstracts International $g 64-01B.
790 $a 0544
790 1 0 $a Johnson, Michael D., $e advisor
791 $a Ph.D.
792 $a 2002
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3077286